Search

Your search keyword '"Roobol, Monique J."' showing total 1,733 results
Start Over Author "Roobol, Monique J."
1,733 results on '"Roobol, Monique J."'

51. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer

Author

Smith, Emma Jane, N'Dow, James, Plass, Karin, Ribal, Maria, Mottet, Nicolas, Shepherd, Robert, Moris, Lisa, Lardas, Michael, Van den Broeck, Thomas, Willemse, Peter-Paul, Campi, Riccardo, Gacci, Mauro, Bjartell, Anders, Evans-Axelsson, LU Susan, Briganti, Alberto, Gandaglia, Giorgio, Crosti, Daniele, Meoni, Massimiliano, Garzonio, Roberto, Bangma, Chris, Roobol, Monique, Remmers, Sebastiaan, Tilki, Derya, Auvinen, Anssi, Murtola, Teemu, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Van Hemelrijck, Mieke, Beyer, Katharina, Lejeune, Stephane, van Diggelen, Femke, Byrne, Sophie, Fialho, Luz, Cardone, Antonella, Gono, Paulina, De Meulder, Bertrand, Auffray, Charles, Balaur, Irina-Afrodita, Taibi, Nesrine, Power, Shaun, Kermani, Nazanin Zounemat, van Bochove, Kees, Cirillo, Elisa, Moinat, Maxim, Voss, Emma, Horgan, Denis, Fullwood, Louise, Holtorf, Marc, Lancet, Doron, Bernstein, Gabi, Omar, Imran, MacLennan, Sara, MacLennan, Steven, Tripathee, Sheela, Huber, Johannes, Wirth, Manfred, Froehner, Michael, Brenner, Beate, Borkowetz, Angelika, Thomas, Christian, Horn, Friedemann, Reiche, Kristin, Kreuz, Markus, Josefsson, Andreas, Tandefelt, Delila Gasi, Hugosson, Jonas, Schalken, Jack, Huisman, Henkjan, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Fridhammar, Adam, Asiimwe, Alex, Verholen, Frank, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Chandrawansa, Kumari, Waldeck, Reg, Molnar, Megan, Bruno, Amanda, Herrera, Ronald, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Mohamed, Ateesha, Steinbeißer, Carl, Kedhagae, Siddhanth, Maass, Monika, Torremante, Patrizia, Voss, Marc Dietrich, Devecseri, Zsuzsanna, Abbott, Tom, Kiran, Amit, Dau, Chad, Papineni, Kishore, Wang-silvanto, Jing, Hass, Steve, Snijder, Robert, Doyé, Verena, Wang, Xuewei, Garnham, Andy, Lambrecht, Mark, Wolfinger, Russ, Rogiers, Stijn, Servan, Angela, Casariego, Joaquin, Samir, Mohamed, Pascoe, Katie, Robinson, Paul, Reich, Christian, Ratwani, Shilpa, Longden-Chapman, Elaine, Burke, Danny, Agapow, Paul, Derkits, Sahra, Licour, Muriel, Ang, Michelle, Payne, Sarah, Yong, Alan, Thompson, Lucy, Le Mare, Sophia, Bussmann, Michael, Köhler, Inken, Juckeland, Guido, Kotik, Daniel, MacLennan, Sara J., Mastris, Ken, Hooker, Gary, Greene, Robert, Briers, Erik, Omar, Muhammad Imran, Healey, Jemma, Venderbos, Lionne D.F., Smith, Emma J., Bjorkqvist, Josefine, Roobol, Monique J., and N’Dow, James

Published
2021
Full Text
View/download PDF

53. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN

Author

Hirama, Hiromi, Sugimoto, Mikio, Miyatake, Nobuyuki, Kato, Takuma, Venderbos, Lionne D. F., Remmers, Sebastiaan, Shiga, Kenichiro, Yokomizo, Akira, Mitsuzuka, Koji, Matsumoto, Ryuji, Osawa, Takahiro, Abe, Takashige, Sasaki, Hiroshi, Egawa, Shin, Ninomiya, Iku, Hashine, Katsuyoshi, Roobol, Monique J., and Kakehi, Yoshiyuki

Published
2021
Full Text
View/download PDF

56. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Author

Conti, David V., Darst, Burcu F., Moss, Lilit C., Saunders, Edward J., Sheng, Xin, Chou, Alisha, Schumacher, Fredrick R., Olama, Ali Amin Al, Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Sahimi, Ali, Hoffmann, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Muir, Kenneth, Lophatananon, Artitaya, Wan, Peggy, Le Marchand, Loic, Wilkens, Lynne R., Stevens, Victoria L., Gapstur, Susan M., Carter, Brian D., Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokołorczyk, Dominika, Lubiński, Jan, Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Børge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Martin Andreas, Iversen, Peter, Batra, Jyotsna, Chambers, Suzanne, Moya, Leire, Horvath, Lisa, Clements, Judith A., Tilley, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordström, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Albanes, Demetrius, Weinstein, Stephanie J., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie-Élise, Stanford, Janet L., Ostrander, Elaine A., Geybels, Milan S., Koutros, Stella, Freeman, Laura E. Beane, Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan-Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M. L., Burnet, Neil, Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Géraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay-Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Fontham, Elizabeth T. H., Mohler, James, Taylor, Jack A., Kogevinas, Manolis, Llorca, Javier, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Weaver, Brandi, Brenner, Hermann, Cuk, Katarina, Holleczek, Bernd, Saum, Kai-Uwe, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J. M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine, Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer C., Petrovics, Gyorgy, Casey, Graham, Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Hu, Jennifer J., Sanderson, Maureen, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Mancuso, Nicholas, Berndt, Sonja I., Van Den Eeden, Stephen K., Easton, Douglas F., Chanock, Stephen J., Cook, Michael B., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Eeles, Rosalind A., Kote-Jarai, Zsofia, and Haiman, Christopher A.

Published
2021
Full Text
View/download PDF

61. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M., Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Frydenberg, Mark, Kakehi, Yoshiyuki, Chung, Byung Ha, van der Kwast, Theo, Obbink, Henk, van der Linden, Wim, Hulsen, Tim, Jonge, Cees de, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Nieboer, Daan, Zhang, Liying, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, Bruinsma, Sophie, Helleman, Jozien, Kalapara, Arveen A., Verbeek, Jan F.M., Lee, Lui Shiong, Bangma, Chris H., Steyerberg, Ewout W., Harkin, Tim, and Roobol, Monique J.

Published
2020
Full Text
View/download PDF

62. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

Author

Travis, Ruth C, Appleby, Paul N, Martin, Richard M, Holly, Jeff MP, Albanes, Demetrius, Black, Amanda, Bueno-de-Mesquita, HB As, Chan, June M, Chen, Chu, Chirlaque, Maria-Dolores, Cook, Michael B, Deschasaux, Mélanie, Donovan, Jenny L, Ferrucci, Luigi, Galan, Pilar, Giles, Graham G, Giovannucci, Edward L, Gunter, Marc J, Habel, Laurel A, Hamdy, Freddie C, Helzlsouer, Kathy J, Hercberg, Serge, Hoover, Robert N, Janssen, Joseph AMJL, Kaaks, Rudolf, Kubo, Tatsuhiko, Le Marchand, Loic, Metter, E Jeffrey, Mikami, Kazuya, Morris, Joan K, Neal, David E, Neuhouser, Marian L, Ozasa, Kotaro, Palli, Domenico, Platz, Elizabeth A, Pollak, Michael, Price, Alison J, Roobol, Monique J, Schaefer, Catherine, Schenk, Jeannette M, Severi, Gianluca, Stampfer, Meir J, Stattin, Pär, Tamakoshi, Akiko, Tangen, Catherine M, Touvier, Mathilde, Wald, Nicholas J, Weiss, Noel S, Ziegler, Regina G, Key, Timothy J, and Allen, Naomi E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Prostate Cancer, Cancer, Urologic Diseases, Aged, Humans, Insulin-Like Growth Factor I, Male, Middle Aged, Prostatic Neoplasms, Risk Factors, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from 17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. After mutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300. ©2016 AACR.

Published
2016

66. Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial

Author

Tiedje, Dorothee, Borowski, Matthias, Simbrich, Alexandra, Schlößler, Kathrin, Kruse, Klaus, Bothe, Christiane, Kuss, Katrin, Adarkwah, Charles Christian, Maisel, Peter, Jendyk, Ralf, Kurosinski, Marc-André, Gerß, Joachim, Tschuschke, Christian, Becker, Ralf, Roobol, Monique J., Bangma, Chris H., Hense, Hans-Werner, Donner-Banzhoff, Norbert, and Semjonow, Axel

Published
2021
Full Text
View/download PDF

67. Comparison of Tumor Volume Parameters on Prostate Cancer Biopsies

Author

Verhoef, Esther I., Kweldam, Charlotte F., Kummerlin, Intan P., Nieboer, Daan, Bangma, Chris H., Incrocci, Luca, van der Kwast, Theodorus H., Roobol, Monique J., and van Leenders, Geert J.L.H.

Subjects
Antigens -- Usage -- Analysis, Cancer screening -- Usage -- Analysis, Tumors -- Prognosis, Prostate cancer -- Prognosis, Health, World Health Organization
Abstract

Context.--Prostate biopsy reports require an indication of prostate cancer volume. No consensus exists on the methodology of tumor volume reporting. Objective.--To compare the prognostic value of different biopsy prostate cancer volume parameters. Design.--Prostate biopsies of the European Randomized Study of Screening for Prostate Cancer were reviewed (n = 1031). Tumor volume was quantified in 6 ways: average estimated tumor percentage, measured total tumor length, average calculated tumor percentage, greatest tumor length, greatest tumor percentage, and average tumor percentage of all biopsies. Their prognostic value was determined by using either logistic regression for extraprostatic expansion (EPE) and surgical margin status after radical prostatectomy (RP), or Cox regression for biochemical recurrence-free survival (BCRFS) and diseasespecific survival (DSS) after RP (n = 406) and radiation therapy (RT) (n = 508). Results.--All tumor volume parameters were significantly mutually correlated ([R.sup.2] > 0.500, P < .001). None were predictive for EPE, surgical margin, or BCRFS after RP in multivariable analysis, including age, prostate-specific antigen, number of positive biopsies, and grade group. In contrast, all tumor volume parameters were significant predictors for BCRFS (all P < .05) and DSS (all P < .05) after RT, except greatest tumor length. In multivariable analysis including only all tumor volume parameters as covariates, calculated tumor length was the only predictor for EPE after RP (P = .02) and DSS after RT (P = .02). Conclusions.--All tumor volume parameters had comparable prognostic value and could be used in clinical practice. If tumor volume quantification is a threshold for treatment decision, calculated tumor length seems preferential, slightly outperforming the other parameters. doi: 10.5858/arpa.2019-0361-OA, Men suspected of having prostate cancer undergo biopsies to determine the presence and aggressiveness of a potential tumor. Apart from Gleason score (GS) and number of positive biopsies, an indication [...]

Published
2020
Full Text
View/download PDF

75. Performance of magnetic resonance imaging‐based prostate cancer risk calculators and decision strategies in two large European medical centres.

Author

Davik, Petter, Remmers, Sebastiaan, Elschot, Mattijs, Roobol, Monique J., Bathen, Tone Frost, and Bertilsson, Helena

Subjects
DISEASE risk factors, ENDORECTAL ultrasonography, MAGNETIC resonance, PROSTATE cancer, MAGNETIC resonance imaging
Abstract

Objectives: To compare the performance of currently available biopsy decision support tools incorporating magnetic resonance imaging (MRI) findings in predicting clinically significant prostate cancer (csPCa). Patients and Methods: We retrospectively included men who underwent prostate MRI and subsequent targeted and/or systematic prostate biopsies in two large European centres. Available decision support tools were identified by a PubMed search. Performance was assessed by calibration, discrimination, decision curve analysis (DCA) and numbers of biopsies avoided vs csPCa cases missed, before and after recalibration, at risk thresholds of 5%–20%. Results: A total of 940 men were included, 507 (54%) had csPCa. The median (interquartile range) age, prostate‐specific antigen (PSA) level, and PSA density (PSAD) were 68 (63–72) years, 9 (7–15) ng/mL, and 0.20 (0.13–0.32) ng/mL2, respectively. In all, 18 multivariable risk calculators (MRI‐RCs) and dichotomous biopsy decision strategies based on MRI findings and PSAD thresholds were assessed. The Van Leeuwen model and the Rotterdam Prostate Cancer Risk Calculator (RPCRC) had the best discriminative ability (area under the receiver operating characteristic curve 0.86) of the MRI‐RCs that could be assessed in the whole cohort. DCA showed the highest clinical utility for the Van Leeuwen model, followed by the RPCRC. At the 10% threshold the Van Leeuwen model would avoid 22% of biopsies, missing 1.8% of csPCa, whilst the RPCRC would avoid 20% of biopsies, missing 2.6% of csPCas. These multivariable models outperformed all dichotomous decision strategies based only on MRI‐findings and PSAD. Conclusions: Even in this high‐risk cohort, biopsy decision support tools would avoid many prostate biopsies, whilst missing very few csPCa cases. The Van Leeuwen model had the highest clinical utility, followed by the RPCRC. These multivariable MRI‐RCs outperformed and should be favoured over decision strategies based only on MRI and PSAD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

76. Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium.

Author

Beyer, Katharina, Leenen, Renée, Venderbos, Lionne D. F., Helleman, Jozien, Denijs, Frederique, Bramer, Wichor, Vasilyeva, Vera, Briers, Erik, Rivas, Juan Gomez, Chloupkova, Renata, Majek, Ondrej, Annemans, Lieven, Vynckier, Pieter, Basu, Partha, Chandran, Arunah, van den Bergh, Roderick, Collen, Sarah, van Poppel, Hendrik, and Roobol, Monique J.

Subjects
MEDICAL screening, EARLY detection of cancer, PROSTATE cancer, HEALTH policy, SCIENTIFIC literature
Abstract

With the new policy recommendation in 2022 to explore the possibilities of screening for prostate cancer by the European Commission, the landscape for prostate cancer early detection is evolving. In line with this recommendation, the PRAISE-U project aims to evaluate the early detection and diagnosis of prostate cancer through customised and risk-based screening programmes, with the goal to align protocols across European Union member states. This systematic review is part of the PRAISE-U project, with the goal to review the policy, medical guideline recommendations, and the current level of opportunistic screening presented in the scientific literature on prostate cancer early detection from 2016 to 2023 in European Union member states. An extensive literature search was performed on 1 June 2023 in a large number of databases, including Embase.com, Medline (Ovid), Web of Science Core Collection, Google Scholar, and Policy Commons. We identified 318 articles (qualitative, quantitative, and reviews), of which 41 were included in the full-text screening. Seventeen articles were ultimately identified as eligible for inclusion. The included articles revealed significant variations towards PSA-based early detection policies for prostate cancer in nine European countries. Despite official recommendations, opportunistic screening was prevalent across all nine countries regardless of recommendations for or against PSA-based early detection. This systematic review suggests that the current early detection policies are not fit for purpose. High levels of opportunistic screening and overdiagnosis persist, prompting policy recommendations for standardised guidelines, informed decision making, and increased awareness to improve efficiency and effectiveness in early detection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

79. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

Author

Darst, Burcu F., primary, Shen, Jiayi, additional, Madduri, Ravi K., additional, Rodriguez, Alexis A., additional, Xiao, Yukai, additional, Sheng, Xin, additional, Saunders, Edward J., additional, Dadaev, Tokhir, additional, Brook, Mark N., additional, Hoffmann, Thomas J., additional, Muir, Kenneth, additional, Wan, Peggy, additional, Le Marchand, Loic, additional, Wilkens, Lynne, additional, Wang, Ying, additional, Schleutker, Johanna, additional, MacInnis, Robert J., additional, Cybulski, Cezary, additional, Neal, David E., additional, Nordestgaard, Børge G., additional, Nielsen, Sune F., additional, Batra, Jyotsna, additional, Clements, Judith A., additional, Cancer BioResource, Australian Prostate, additional, Grönberg, Henrik, additional, Pashayan, Nora, additional, Travis, Ruth C., additional, Park, Jong Y., additional, Albanes, Demetrius, additional, Weinstein, Stephanie, additional, Mucci, Lorelei A., additional, Hunter, David J., additional, Penney, Kathryn L., additional, Tangen, Catherine M., additional, Hamilton, Robert J., additional, Parent, Marie-Élise, additional, Stanford, Janet L., additional, Koutros, Stella, additional, Wolk, Alicja, additional, Sørensen, Karina D., additional, Blot, William J., additional, Yeboah, Edward D., additional, Mensah, James E., additional, Lu, Yong-Jie, additional, Schaid, Daniel J., additional, Thibodeau, Stephen N., additional, West, Catharine M., additional, Maier, Christiane, additional, Kibel, Adam S., additional, Cancel-Tassin, Géraldine, additional, Menegaux, Florence, additional, John, Esther M., additional, Grindedal, Eli Marie, additional, Khaw, Kay-Tee, additional, Ingles, Sue A., additional, Vega, Ana, additional, Rosenstein, Barry S., additional, Teixeira, Manuel R., additional, Kogevinas, Manolis, additional, Cannon-Albright, Lisa, additional, Huff, Chad, additional, Multigner, Luc, additional, Kaneva, Radka, additional, Leach, Robin J., additional, Brenner, Hermann, additional, Hsing, Ann W., additional, Kittles, Rick A., additional, Murphy, Adam B., additional, Logothetis, Christopher J., additional, Neuhausen, Susan L., additional, Isaacs, William B., additional, Nemesure, Barbara, additional, Hennis, Anselm J., additional, Carpten, John, additional, Pandha, Hardev, additional, De Ruyck, Kim, additional, Xu, Jianfeng, additional, Razack, Azad, additional, Teo, Soo-Hwang, additional, Newcomb, Lisa F., additional, Fowke, Jay H., additional, Neslund-Dudas, Christine, additional, Rybicki, Benjamin A., additional, Gamulin, Marija, additional, Usmani, Nawaid, additional, Claessens, Frank, additional, Gago-Dominguez, Manuela, additional, Castelao, Jose Esteban, additional, Townsend, Paul A., additional, Crawford, Dana C., additional, Petrovics, Gyorgy, additional, Casey, Graham, additional, Roobol, Monique J., additional, Hu, Jennifer F., additional, Berndt, Sonja I., additional, Van Den Eeden, Stephen K., additional, Easton, Douglas F., additional, Chanock, Stephen J., additional, Cook, Michael B., additional, Wiklund, Fredrik, additional, Witte, John S., additional, Eeles, Rosalind A., additional, Kote-Jarai, Zsofia, additional, Watya, Stephen, additional, Gaziano, John M., additional, Justice, Amy C., additional, Conti, David V., additional, and Haiman, Christopher A., additional

Published
2023
Full Text
View/download PDF

80. Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data

Author

Gandaglia, Giorgio, primary, Pellegrino, Francesco, additional, Golozar, Asieh, additional, De Meulder, Bertrand, additional, Abbott, Thomas, additional, Achtman, Ariel, additional, Imran Omar, Muhammad, additional, Alshammari, Thamir, additional, Areia, Carlos, additional, Asiimwe, Alex, additional, Beyer, Katharina, additional, Bjartell, Anders, additional, Campi, Riccardo, additional, Cornford, Philip, additional, Falconer, Thomas, additional, Feng, Qi, additional, Gong, Mengchun, additional, Herrera, Ronald, additional, Hughes, Nigel, additional, Hulsen, Tim, additional, Kinnaird, Adam, additional, Lai, Lana Y.H., additional, Maresca, Gianluca, additional, Mottet, Nicolas, additional, Oja, Marek, additional, Prinsen, Peter, additional, Reich, Christian, additional, Remmers, Sebastiaan, additional, Roobol, Monique J., additional, Sakalis, Vasileios, additional, Seager, Sarah, additional, Smith, Emma J., additional, Snijder, Robert, additional, Steinbeisser, Carl, additional, Thurin, Nicolas H., additional, Hijazy, Ayman, additional, van Bochove, Kees, additional, Van den Bergh, Roderick C.N., additional, Van Hemelrijck, Mieke, additional, Willemse, Peter-Paul, additional, Williams, Andrew E., additional, Zounemat Kermani, Nazanin, additional, Evans-Axelsson, Susan, additional, Briganti, Alberto, additional, and N'Dow, James, additional

Published
2023
Full Text
View/download PDF

82. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy

Author

Mannaerts, Christophe K., Gayet, Maudy, Verbeek, Jan F., Engelbrecht, Marc R.W., Savci-Heijink, C. Dilara, Jager, Gerrit J., Gielens, Maaike P.M., van der Linden, Hans, Beerlage, Harrie P., de Reijke, Theo M., Wijkstra, Hessel, and Roobol, Monique J.

Published
2018
Full Text
View/download PDF

84. How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration

Author

Májek, Ondřej, Babjuk, Marek, Roobol, Monique J., Bratt, Ola, Van Poppel, Hendrik, Zachoval, Roman, Ferda, Jiří, Koudelková, Marcela, Ngo, Ondřej, Gregor, Jakub, Collen, Sarah, Hejduk, Karel, Dušek, Ladislav, Válek, Vlastimil, and Urology

Subjects
SDG 3 - Good Health and Well-being
Abstract

An updated Council of the EU recommendation on cancer screening was adopted in December 2022 during the Czech EU presidency. The recommendation included prostate cancer as a suitable target disease for organised screening, and invited countries to proceed with piloting and further research. To support further discussions and actions to promote early detection of prostate cancer, an international conference in November 2022 (Prostaforum 2022) resulted in a joint declaration. Here we describe the EU policy background, summarise the preparation of the declaration and the key underlying evidence and expert recommendations, and report the text of the declaration. The declaration summarises the striking inequalities in prostate cancer burden in Europe and calls on all stakeholders to consider and support concrete steps for advancement of organised early detection of prostate cancer. Our aim is to request endorsement of the text and potential initiation of practical actions by all stakeholders to support the aims of the declaration. Patient summary: Prostate cancer is among the most frequent cancers and is one of the most common causes of cancer death among men. The European Union has recommended new pilot programmes for prostate cancer screening. The Prostaforum 2022 declaration invites all stakeholders to support this new recommendation with specific steps.

Published
2023

85. An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk

Author

Wu, Lang, Yang, Yaohua, Guo, Xingyi, Shu, Xiao-Ou, Cai, Qiuyin, Shu, Xiang, Li, Bingshan, Tao, Ran, Wu, Chong, Nikas, Jason B., Sun, Yanfa, Zhu, Jingjing, Roobol, Monique J., Giles, Graham G., Brenner, Hermann, John, Esther M., Clements, Judith, Grindedal, Eli Marie, Park, Jong Y., Stanford, Janet L., Kote-Jarai, Zsofia, Haiman, Christopher A., Eeles, Rosalind A., Zheng, Wei, and Long, Jirong

Published
2020
Full Text
View/download PDF

86. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?

Author

Smith, Emma, N'Dow, James, Plass, Karin, Ribal, Maria, Mottet, Nicolas, Shepherd, Robert, Abbott, Tom, Mastris, Ken, Moris, Lisa, Lardas, Michael, Van den Broeck, Thomas, Willemse, Peter-Paul, Fossati, Nicola, Pang, Karl, Campi, Riccardo, Greco, Isabella, Gacci, Mauro, Serni, Sergio, Bjartell, Anders, Lonnerbro, Ragnar, Briganti, Alberto, Crosti, Daniele, Garzonio, Roberto, Gandaglia, Giorgio, Faticoni, Martina, Grant office, Bangma, Chris, Jongerden, Maria, Tilki, Derya, Auvinen, Anssi, Murtola, Teemu, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Lejeune, Stephane, Colette, Laurence, Caputova, Simona, Poli, Delielena, Byrne, Sophie, Fialho, Luz, Rowland, Ashley, Tapela, Neo, Di Flora, Nicola, Apostolidis, Kathi, Lemair, Valerie, De Meulder, Bertrand, Auffray, Charles, Taibi, Nesrine, Hijazy, Ayman, Saporta, Albert, Sun, Kai, Power, Shaun, Zounemat Kermani, Nazanin, van Bochove, Kees, Tafreshiha, Azadeh, Bernini, Chiara, Horgan, Denis, Fullwood, Louise, Holtorf, Marc, Lancet, Doron, Bernstein, Gabi, Tripathee, Sheela, Wirth, Manfred, Froehner, Michael, Brenner, Beate, Borkowetz, Angelika, Thomas, Christian, Horn, Friedemann, Reiche, Kristin, Kreuz, Markus, Josefsson, Andreas, Gasi Tandefelt, Delila, Hugosson, Jonas, Schalken, Jack, Huisman, Henkjan, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Fridhammar, Adam, Tames Grijalva, Monica, Evans-Axelsson, Susan, Verholen, Frank, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Waldeck, Reg, Bruno, Amanda, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Steinbeisser, Carl, Maass, Monika, Torremante, Patrizia, Dochy, Emmanuelle, Pisa, Federica, Voss, Marc Dietrich, Papineni, Kishore, Wang-silvanto, Jing, Snijder, Robert, Wang, Xuewei, Lambrecht, Mark, Wolfinger, Russ, Eid, Sherinne, Palanisamy, Soundarya, Haque, Samiul, Antoni, Laurent, Servan, Angela, Pascoe, Katie, Robinson, Paul, Lencart, Joana, Jaton, Bertrand, Turunen, Heidi, Kilkku, Olavi, Pohjanjousi, Pasi, Voima, Olli, Nevalaita, Liina, Punakivi, Keijo, Seager, Sarah, Ratwani, Shilpa, Grzeslak, Katarzyna, Brash, James, Longden-Chapman, Elaine, Burke, Danny, Licour, Muriel, Payne, Sarah, Yong, Alan, Lujan, Flavia, Le Mare, Sophia, Hendrich, Jan, Bussmann, Michael, Juckeland, Kotik, Reich, Christian, Russell, Beth, Beyer, Katharina, Lawlor, Ailbhe, Roobol, Monique J., Venderbos, Lionne D.F., Remmers, Sebastiaan, Briers, Erik, MacLennan, Sara J., MacLennan, Steven, Omar, Muhammad Imran, and Van Hemelrijck, Mieke

Published
2024
Full Text
View/download PDF

89. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

Author

MacLennan, Steven, primary, Azevedo, Nuno, additional, Duncan, Eilidh, additional, Dunsmore, Jennifer, additional, Fullwood, Louise, additional, Lumen, Nicolaas, additional, Plass, Karin, additional, Ribal, Maria J., additional, Roobol, Monique J., additional, Nieboer, Daan, additional, Schouten, Natasha, additional, Skolarus, Ted A., additional, Smith, Emma Jane, additional, N'Dow, James, additional, Mottet, Nicolas, additional, Briganti, Alberto, additional, Heidegger, Isabel, additional, Resch, Johannes Mischinger Irene, additional, Turba, Simon, additional, Zeder, Robin, additional, Lodeta, Braninimir, additional, Van Praet, Charles, additional, Ghysel, Christophe, additional, Arentsen, Harm C., additional, Beysens, Matthias, additional, Vinckier, Marie-Hélène, additional, Mottrie, Alexandre, additional, de Groote, Ruben, additional, Timev, Aleksandar Ivanov, additional, Georgiev, Marincho Ivanov, additional, Yanev, Krassimir Prodanov, additional, Mladenov, Boris, additional, Ivanov, Atanas Slavchev, additional, Antonov, Petar, additional, Valkanov, Stanislav, additional, Tomašković, Igor, additional, Kulis, Tomislav, additional, Bokarica, Pero, additional, Pavlović, Oliver, additional, Krajina, Vinko, additional, Situm, Marijan, additional, Boban, Toni, additional, Soric, Tomislav, additional, Vidic, Ivan, additional, Benko, Goran, additional, Peršec, Zoran, additional, Sović, Tomislav, additional, Zachoval, Roman, additional, Stejskal, Jiri, additional, Capoun, Otakar, additional, Pitra, Tomáš, additional, Gojdič, Marek, additional, Babjuk, Marek, additional, Novák, Vojtěch, additional, Grepl, Michal, additional, Broul, Marek, additional, Novák, Jan, additional, Lund, Lars, additional, Nordström Joensen, Ulla, additional, Borre, Michael, additional, Veskimäe, Priit, additional, Baum, Peep, additional, Tamm, Toomas, additional, Okas, Rauno, additional, Jämsä, Pyry, additional, Lahdensuo, Kanerva, additional, Siltari, Sirkku, additional, Seikkula, Heikki, additional, Palmberg, Christian, additional, Isotalo, Taina, additional, Fiard, Gaelle, additional, Verrier, Cecile, additional, Wiedemann, Laura, additional, Lecornet, Emilie, additional, Leon, Priscilla, additional, Millet, Clementine, additional, Ponzio, Charles, additional, Ploussard, Guillaume, additional, Xylinas, Evanguelos, additional, Ingels, Alexandre, additional, Bigot, Pierre, additional, Le Corre, Vincent, additional, Audenet, François, additional, Berg, Sebastian, additional, Palisaar, Rein-Jueri, additional, Heidenreich, Axel, additional, Seelemeyer, Felix, additional, Krege, Susanne, additional, Leyh-Bannurah, Sami-Ramzi, additional, Witt, Jörn H., additional, Abdirahman, Ayanle, additional, Truß, Michael C., additional, Kranz, Jennifer, additional, Andreas, Karagiannis, additional, Vassileios, Tzortzis, additional, Andreas, Andreou, additional, Paparidis, Spyridon, additional, Davis, Nikolaos Ferakis Niall F., additional, Keane, Kevin G., additional, Fuentes, Adrian, additional, Scuderi, Simone, additional, Barletta, Francesco, additional, Manfredi, Matteo, additional, Porpiglia, Francesco, additional, Cerruto, Maria Angela, additional, Antonelli, Alessandro, additional, Esperto, Francesco, additional, Rossanese, Marta, additional, Veneziano, Domenico, additional, Castelli, Tommaso, additional, La Rocca, Roberto, additional, Scarcia, Marcello, additional, Mantica, Guglielmo, additional, Rebuffo, Silvia, additional, Pomara, Giorgio, additional, Pavan, Nicola, additional, Silvestri, Tommaso, additional, Reale, Giulio Francesco, additional, Polara, Andrea, additional, Falagario, Ugo Giovanni, additional, Carrieri, Giuseppe, additional, Ferrari, Giovanni, additional, Brausi, Maurizio, additional, Orecchia, Luca, additional, Annino, Filippo, additional, Kazlauskas, Gražvydas, additional, Stavridis, Sotir, additional, Radovic, Nenad, additional, Vukovic, Marko, additional, van der Slot, Margaretha Adriana, additional, Bruins, Harman Maxim, additional, van Oort, Inge, additional, Witjes, Fred, additional, van der Poel, Henk, additional, Beisland, Christian, additional, Lilleåsenm, Gunder, additional, Müller, Stig, additional, Haug, Erik S., additional, Dimmen, Magne, additional, Czech, Anna K., additional, Nyk, Lukasz, additional, Jaskulski, Jaroslaw, additional, Ratajczyk, Krzysztof, additional, Braga, Isaac, additional, Pereira, João, additional, Lúcio, Rui, additional, Pina, João, additional, da Silva, Edgar Miguel Calvo Loureiro Tavares, additional, Furriel, Frederico, additional, Mota, Paulo, additional, Rodrigues, Miguel, additional, Radavoi, George Daniel, additional, Crisan, Nicolae, additional, Andras, Iulia, additional, Robert, Stoica, additional, Bratu, Ovidiu, additional, Surcel, Cristian, additional, Kotov, Sergei, additional, Malkhasyan, Vigen, additional, Petrov, Sergei, additional, Reva, Sergei, additional, Bumbasirevic, Uros, additional, Kováčik, Viktor, additional, Perečinský, Ivan, additional, Rybár, Ľuboš, additional, Šulgan, Ján, additional, Briš, Lukáš, additional, Jursová, Katarína, additional, Chovan, Miroslav, additional, Kička, Tomáš, additional, Taskovska, Milena, additional, Kovačič, Rok, additional, Miklavžina, Andraž, additional, Alvarez-Maestro, Mario, additional, De Castro, Javier Mayor, additional, Aragón-Chamizo, Juan, additional, Sutil, Raquel Sopeña, additional, Perrello, Carmen Garau, additional, Vilaseca, Antoni, additional, Perez, Jorge Huguet, additional, Ovide, Julia Aumatell, additional, Planas, Jacques, additional, Borque-Fernando, Angel, additional, Sánchez-Izquierdo, Elena, additional, Jimenez, Jose Luis Marenco, additional, Lendínez-Cano, Guillermo, additional, Puche-Sanz, Ignacio, additional, Garcia-Baquero, Rodrigo, additional, Esteban, Mario Domínguez, additional, Pérez-Fentes, Daniel, additional, Serván, Patricia Parra, additional, Koskela, Lotta Renström, additional, Stranne, Johan, additional, Scholtz, Bianca, additional, Torbrand, Christian, additional, Wagenius, Magnus, additional, Ugge, Henrik, additional, Örtegren, Joakim, additional, Langenauer, Janine, additional, Zumstein, Valentin, additional, Schmid, Hans Peter, additional, Rieken, Malte, additional, Saba, Karim, additional, Strebel, Raeto T., additional, Mortezavi, Ashkan, additional, Rentsch, Cyrill, additional, Roth, Beat, additional, Eberli, Daniel, additional, Pascal, Oechslin, additional, Auer, Rebecca, additional, John, Hubert, additional, Thalmann, George N., additional, Baltacı, Sümer, additional, Mungan, Aydın, additional, Sözen, Sinan, additional, Cetin, Serhat, additional, Aslan, Guven, additional, Türkeri, Levent, additional, İzol, Volkan, additional, Demirdağ, Çetin, additional, Ozden, Sami Berk, additional, Toktaş, Gökhan, additional, Sarikaya, Şaban, additional, Tinay, İlker, additional, Müezzinoğlu, Talha, additional, Erbatu, Oguzcan, additional, Sagnak, Levent, additional, Akdoğan, Bülent, additional, Can, Cavit, additional, Şahin, Hayrettin, additional, Yazıcı, Cenk Murat, additional, Volkov, Serhii, additional, Shulyak, Olexandr, additional, Douglas, David, additional, Hemmant, Joshua, additional, El-Taji, Omar, additional, Ahmad, Imran, additional, Nalagatla, Sarika, additional, Janebdar, Husay, additional, Veeratterapillay, Rajan, additional, Rai, Bhavan, additional, Conroy, Samantha, additional, Cumberbatch, Marcus, additional, and Malde, Sachin, additional

Published
2023
Full Text
View/download PDF

90. External validation of the Rotterdam Prostate Cancer Risk Calculator within a Dutch high-risk clinical cohort

Author

Hagens, Marinus J., primary, Stelwagen, Piter J., additional, Veerman, Hans, additional, Rynja, Sybren P., additional, Smeenge, Martijn, additional, van der Noort, Vincent, additional, Roeleveld, Ton A., additional, van Kesteren, Jolien, additional, Remmers, Sebastiaan, additional, Roobol, Monique J., additional, van Leeuwen, Pim J., additional, and van der Poel, Henk G., additional

Published
2023
Full Text
View/download PDF

95. Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program.

Author

Gomez Rivas, Juan, Nicoletti, Rossella, Ibáñez, Laura, Steinbeisser, Carl, de Meulder, Bertrand, Golozar, Asieh, Evans Axelsson, Susan, Snijder, Robert, Bjartell, Anders, Cornford, Philip, Van Hemelrijck, Mieke, Beyer, Katharina, Willemse, Peter-Paul, Murtola, Teemu, Roobol, Monique J., Moreno-Sierra, Jesús, Campi, Riccardo, Gacci, Mauro, Mottet, Nicolas, and Merseburger, Axel

Published
2023
Full Text
View/download PDF

96. Navigating through the Controversies and Emerging Paradigms in Early Detection of Prostate Cancer: Bridging the Gap from Classic RCTs to Modern Population-Based Pilot Programs.

Author

Gómez Rivas, Juan, Leenen, Renée C. A., Venderbos, Lionne D. F., Helleman, Jozien, de la Parra, Irene, Vasilyeva, Vera, Moreno-Sierra, Jesús, Basu, Partha, Chandran, Arunah, van den Bergh, Roderick C. N., Collen, Sarah, Van Poppel, Hein, Roobol, Monique J., and Beyer, Katharina

Subjects
EARLY detection of cancer, PROSTATE cancer, MEDICAL screening, PILOT projects, PROSTATE biopsy, CANCER-related mortality
Abstract

Over the last three decades, the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening have steered the conversation around the early detection of prostate cancer. These two randomized trials assessed the effect of screening on prostate cancer disease-specific mortality. Elevated PSA levels were followed by a systematic sextant prostate biopsy. Standard repeat testing intervals were applied. After controversies from 2009 to 2016 due to contradicting results of the two trials, the results aligned in 2016 and showed that early PSA detection reduces prostate cancer-specific mortality. However, overdiagnosis rates of up to 50% were reported, and this sparked an intense debate on harms and benefits for almost 20 years. The balance between harms and benefits is highly debated and has initiated further research to investigate new ways of early detection. In the meantime, the knowledge and tools for the diagnostic algorithm improved. This is a continuously ongoing effort which focuses on individual risk-based screening algorithms that preserve the benefits of the purely PSA-based screening algorithms, while reducing the side effects. An important push towards investigating new techniques for early detection came from the European Commission on the 20th of September 2022. The European Commission published its updated recommendation to investigate prostate, lung, and gastric cancer early detection programs. This opened a new window of opportunity to move away from the trial setting to population-based early detection settings. With this review, we aim to review 30 years of historical evidence of prostate cancer screening, which led to the initiation of the 'The Prostate Cancer Awareness and Initiative for Screening in the European Union' (PRAISE-U) project, which aims to encourage the early detection and diagnosis of PCa through customized and risk-based screening programs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

99. Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry

Author

Darst, Burcu F., Shen, Jiayi, Madduri, Ravi K., Rodriguez, Alexis A., Xiao, Yukai, Sheng, Xin, Saunders, Edward J., Dadaev, Tokhir, Brook, Mark N., Hoffmann, Thomas J., Muir, Kenneth, Wan, Peggy, Marchand, Loic Le, Wilkens, Lynne, Wang, Ying, Schleutker, Johanna, MacInnis, Robert J., Cybulski, Cezary, Neal, David E., G. Nordestgaard, Børge, Nielsen, Sune F., Batra, Jyotsna, Clements, Judith A., Grönberg, Henrik, Pashayan, Nora, Travis, Ruth C., Park, Jong Y., Albanes, Demetrius, Weinstein, Stephanie, Mucci, Lorelei A., Hunter, David J., Penney, Kathryn L., Tangen, Catherine M., Hamilton, Robert J., Parent, Marie-Élise, Stanford, Janet L., Koutros, Stella, Wolk, Alicja, Sørensen, Karina D., Blot, William J., Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Schaid, Daniel J., Thibodeau, Stephen N., West, Catharine M., Maier, Christiane, Kibel, Adam S., Cancel-Tassin, Géraldine, Menegaux, Florence, John, Esther M., Grindedal, Eli Marie, Khaw, Kay-Tee, Ingles, Sue A., Vega, Ana, Rosenstein, Barry S., Teixeira, Manuel R., Kogevinas, Manolis, Cannon-Albright, Lisa, Huff, Chad, Multigner, Luc, Kaneva, Radka, Leach, Robin J., Brenner, Hermann, Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Neuhausen, Susan L., Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J., Carpten, John, Pandha, Hardev, De Ruyck, Kim, Xu, Jianfeng, Razack, Azad, Teo, Soo-Hwang, Newcomb, Lisa F., Fowke, Jay H., Neslund-Dudas, Christine, Rybicki, Benjamin A., Gamulin, Marija, Usmani, Nawaid, Claessens, Frank, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Townsend, Paul A., Crawford, Dana C., Petrovics, Gyorgy, Casey, Graham, Roobol, Monique J., Hu, Jennifer F., Berndt, Sonja I., Van Den Eeden, Stephen K., Easton, Douglas F., Chanock, Stephen J., Cook, Michael B., Wiklund, Fredrik, Witte, John S., Eeles, Rosalind A., Kote-Jarai, Zsofia, Watya, Stephen, Gaziano, John M., Justice, Amy C., Conti, David V., and Haiman, Christopher A.

Subjects
Article
Abstract

Genome-wide polygenic risk scores (GW-PRS) have been reported to have better predictive ability than PRS based on genome-wide significance thresholds across numerous traits. We compared the predictive ability of several GW-PRS approaches to a recently developed PRS of 269 established prostate cancer risk variants from multi-ancestry GWAS and fine-mapping studies (PRS (269) ). GW-PRS models were trained using a large and diverse prostate cancer GWAS of 107,247 cases and 127,006 controls used to develop the multi-ancestry PRS (269) . Resulting models were independently tested in 1,586 cases and 1,047 controls of African ancestry from the California/Uganda Study and 8,046 cases and 191,825 controls of European ancestry from the UK Biobank and further validated in 13,643 cases and 210,214 controls of European ancestry and 6,353 cases and 53,362 controls of African ancestry from the Million Veteran Program. In the testing data, the best performing GW-PRS approach had AUCs of 0.656 (95% CI=0.635-0.677) in African and 0.844 (95% CI=0.840-0.848) in European ancestry men and corresponding prostate cancer OR of 1.83 (95% CI=1.67-2.00) and 2.19 (95% CI=2.14-2.25), respectively, for each SD unit increase in the GW-PRS. However, compared to the GW-PRS, in African and European ancestry men, the PRS (269) had larger or similar AUCs (AUC=0.679, 95% CI=0.659-0.700 and AUC=0.845, 95% CI=0.841-0.849, respectively) and comparable prostate cancer OR (OR=2.05, 95% CI=1.87-2.26 and OR=2.21, 95% CI=2.16-2.26, respectively). Findings were similar in the validation data. This investigation suggests that current GW-PRS approaches may not improve the ability to predict prostate cancer risk compared to the multi-ancestry PRS (269) constructed with fine-mapping.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results